SAB Biotherapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.6079
- Today's High:
- $0.65
- Open Price:
- $0.6079
- 52W Low:
- $0.366
- 52W High:
- $1.45
- Prev. Close:
- $0.611
- Volume:
- 7501
Company Statistics
- Market Cap.:
- $38.37 million
- Book Value:
- 0.377
- Revenue TTM:
- $6.42 million
- Operating Margin TTM:
- -460.42%
- Gross Profit TTM:
- $-12534332
- Profit Margin:
- 0%
- Return on Assets TTM:
- -39.04%
- Return on Equity TTM:
- -102.7%
Company Profile
SAB Biotherapeutics Inc had its IPO on 2021-02-09 under the ticker symbol SABS.
The company operates in the Healthcare sector and Biotechnology industry. SAB Biotherapeutics Inc has a staff strength of 56 employees.
Stock update
Shares of SAB Biotherapeutics Inc opened at $0.61 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.61 - $0.65, and closed at $0.61.
This is a 0% increase from the previous day's closing price.
A total volume of 7,501 shares were traded at the close of the day’s session.
In the last one week, shares of SAB Biotherapeutics Inc have slipped by -16.64%.
SAB Biotherapeutics Inc's Key Ratios
SAB Biotherapeutics Inc has a market cap of $38.37 million, indicating a price to book ratio of 1.3504 and a price to sales ratio of 1.5056.
In the last 12-months SAB Biotherapeutics Inc’s revenue was $6.42 million with a gross profit of $-12534332 and an EBITDA of $-25994734. The EBITDA ratio measures SAB Biotherapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, SAB Biotherapeutics Inc’s operating margin was -460.42% while its return on assets stood at -39.04% with a return of equity of -102.7%.
In Q2, SAB Biotherapeutics Inc’s quarterly earnings growth was a negative -60% while revenue growth was a negative 98.7%.
SAB Biotherapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.68 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into SAB Biotherapeutics Inc’s profitability.
SAB Biotherapeutics Inc stock is trading at a EV to sales ratio of 1.206 and a EV to EBITDA ratio of -2.0318. Its price to sales ratio in the trailing 12-months stood at 1.5056.
SAB Biotherapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $35.44 million
- Total Liabilities
- $11.01 million
- Operating Cash Flow
- $-22684.00
- Capital Expenditure
- $22684
- Dividend Payout Ratio
- 0%
SAB Biotherapeutics Inc ended 2024 with $35.44 million in total assets and $0 in total liabilities. Its intangible assets were valued at $35.44 million while shareholder equity stood at $19.72 million.
SAB Biotherapeutics Inc ended 2024 with $595860.00 in deferred long-term liabilities, $11.01 million in other current liabilities, 5286.00 in common stock, $-62104461.00 in retained earnings and $0 in goodwill. Its cash balance stood at $7.77 million and cash and short-term investments were $7.77 million. The company’s total short-term debt was $784,880 while long-term debt stood at $541644.00.
SAB Biotherapeutics Inc’s total current assets stands at $9.01 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $364117.00 compared to accounts payable of $1.40 million and inventory worth $0.
In 2024, SAB Biotherapeutics Inc's operating cash flow was $-22684.00 while its capital expenditure stood at $22684.
Comparatively, SAB Biotherapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.61
- 52-Week High
- $1.45
- 52-Week Low
- $0.366
- Analyst Target Price
- $3.2
SAB Biotherapeutics Inc stock is currently trading at $0.61 per share. It touched a 52-week high of $1.45 and a 52-week low of $1.45. Analysts tracking the stock have a 12-month average target price of $3.2.
Its 50-day moving average was $0.78 and 200-day moving average was $0.76 The short ratio stood at 12.27 indicating a short percent outstanding of 0%.
Around 3014.4% of the company’s stock are held by insiders while 770.7% are held by institutions.
Frequently Asked Questions About SAB Biotherapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company’s pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.